Tillkännagivande • Apr 29
Serge Ferrari Group Discontinues Pet Spinning Operations At Tersuisse Site and Reduces 62 Jobs Serge Ferrari Group announced a new phase in the rollout of its plan to streamline its industrial operations, with plans to cease operations at the Tersuisse site, its high-tenacity PET (polyethylene terephthalate) yarn production plant located in Emmenbrücke, Switzerland, which employs 62 people. Industrial continuity would be fully ensured through external supplies of PET yarn. The Group would, however, retain the intellectual property and technological expertise related to its specialty yarns. Warping operations would be transferred to the La Tour du Pin site to secure the value chain and keep key expertise at the heart of the industrial infrastructure. In line with its strategic plan, this project aims to strengthen the Group’s competitiveness and industrial flexibility to better address the accelerating pace of change in its business segments. It would result in exceptional expenses in the first half of 2026, with a limited cash impact, but would have a positive effect on operating profitability while reducing capital employed starting in 2027. Tillkännagivande • Apr 23
SergeFerrari Group SA to Report First Half, 2026 Results on Sep 09, 2026 SergeFerrari Group SA announced that they will report first half, 2026 results on Sep 09, 2026 New Risk • Apr 09
New major risk - Financial position The company's interest payments are not well covered by earnings. Net interest cover: 3.0x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (3.0x net interest cover). Minor Risk Market cap is less than US$100m (€80.2m market cap, or US$93.6m). Reported Earnings • Mar 29
Full year 2025 earnings: EPS misses analyst expectations Full year 2025 results: EPS: €0.47 (up from €1.31 loss in FY 2024). Revenue: €347.5m (up 7.4% from FY 2024). Net income: €5.36m (up €20.5m from FY 2024). Profit margin: 1.5% (up from net loss in FY 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 24%. Revenue is forecast to grow 3.9% p.a. on average during the next 2 years, compared to a 4.6% growth forecast for the Chemicals industry in France. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 42 percentage points per year, which is a significant difference in performance. New Risk • Mar 27
New major risk - Revenue and earnings growth Earnings have declined by 45% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.2x net interest cover). Earnings have declined by 45% per year over the past 5 years. Minor Risk Market cap is less than US$100m (€80.0m market cap, or US$92.1m). Buy Or Sell Opportunity • Mar 12
Now 22% undervalued after recent price drop Over the last 90 days, the stock has fallen 17% to €6.80. The fair value is estimated to be €8.70, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company has become profitable. Revenue is forecast to grow by 8.4% in 2 years. Earnings are forecast to grow by 1,433% in the next 2 years. New Risk • Mar 09
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: €82.5m (US$95.8m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (2.2x net interest cover). Minor Risk Market cap is less than US$100m (€82.5m market cap, or US$95.8m). Price Target Changed • Jan 29
Price target increased by 7.7% to €9.33 Up from €8.67, the current price target is an average from 3 analysts. New target price is 9.8% above last closing price of €8.50. Stock is up 57% over the past year. The company is forecast to post earnings per share of €0.62 next year compared to a net loss per share of €1.31 last year. Major Estimate Revision • Oct 22
Consensus EPS estimates fall by 12%, revenue upgraded The consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast increased from €346.8m to €350.8m. EPS estimate fell from €0.583 to €0.513 per share. Net income forecast to grow 1,074% next year vs 14% growth forecast for Chemicals industry in France. Consensus price target up from €8.00 to €8.67. Share price rose 5.9% to €7.50 over the past week. Tillkännagivande • Oct 21
SergeFerrari Group SA to Report Fiscal Year 2025 Results on Mar 11, 2026 SergeFerrari Group SA announced that they will report fiscal year 2025 results After-Market on Mar 11, 2026 New Risk • Sep 12
New major risk - Financial position The company's interest payments are not well covered by earnings. Net interest cover: 2.2x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (2.2x net interest cover). Minor Risk Market cap is less than US$100m (€78.8m market cap, or US$92.4m). Price Target Changed • Aug 01
Price target increased by 7.2% to €7.43 Up from €6.93, the current price target is an average from 3 analysts. New target price is 20% above last closing price of €6.20. Stock is up 6.9% over the past year. The company is forecast to post earnings per share of €0.42 next year compared to a net loss per share of €1.31 last year. Price Target Changed • Jun 25
Price target increased by 10% to €6.93 Up from €6.28, the current price target is an average from 3 analysts. New target price is 34% above last closing price of €5.18. Stock is down 12% over the past year. The company is forecast to post earnings per share of €0.33 next year compared to a net loss per share of €1.31 last year. Tillkännagivande • Apr 25
SergeFerrari Group SA to Report First Half, 2025 Results on Sep 10, 2025 SergeFerrari Group SA announced that they will report first half, 2025 results on Sep 10, 2025 Reported Earnings • Apr 03
Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind Full year 2024 results: €1.31 loss per share (down from €0.40 profit in FY 2023). Revenue: €323.6m (down 1.2% from FY 2023). Net loss: €15.2m (down 422% from profit in FY 2023). Revenue exceeded analyst estimates by 2.9%. Earnings per share (EPS) missed analyst estimates by 53%. Revenue is forecast to grow 4.3% p.a. on average during the next 2 years, compared to a 5.1% growth forecast for the Chemicals industry in France. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 56 percentage points per year, which is a significant difference in performance. Major Estimate Revision • Mar 30
Consensus EPS estimates upgraded to €0.45 loss The consensus outlook for fiscal year 2024 has been updated. 2024 losses forecast to reduce from -€0.507 to -€0.45 per share. Revenue forecast unchanged from €314.5m at last update. Chemicals industry in France expected to see average net income growth of 14% next year. Consensus price target of €6.40 unchanged from last update. Share price fell 2.8% to €5.46 over the past week. Tillkännagivande • Mar 29
SergeFerrari Group SA, Annual General Meeting, May 15, 2025 SergeFerrari Group SA, Annual General Meeting, May 15, 2025. Major Estimate Revision • Nov 05
Consensus EPS estimates fall by 39% The consensus outlook for earnings per share (EPS) in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from €318.7m to €315.1m. Losses expected to increase from €0.47 per share to €0.65. Chemicals industry in France expected to see average net income growth of 28% next year. Consensus price target up from €6.50 to €6.77. Share price rose 11% to €6.12 over the past week. Tillkännagivande • Oct 31
SergeFerrari Group SA to Report Fiscal Year 2024 Results on Mar 27, 2025 SergeFerrari Group SA announced that they will report fiscal year 2024 results on Mar 27, 2025 Buy Or Sell Opportunity • Sep 11
Now 24% overvalued Over the last 90 days, the stock has fallen 8.3% to €5.63. The fair value is estimated to be €4.55, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Earnings per share has grown by 22%. For the next 3 years, revenue is forecast to grow by 2.5% per annum. Earnings are also forecast to grow by 42% per annum over the same time period. Major Estimate Revision • Sep 11
Consensus EPS estimates fall from profit to €0.16 loss The consensus outlook for fiscal year 2024 has been updated. Expected to report loss instead of -€0.162 instead of €0.189 per share profit previously forecast. Revenue forecast unchanged at €322.0m Chemicals industry in France expected to see average net income growth of 23% next year. Consensus price target of €6.50 unchanged from last update. Share price fell 7.6% to €5.45 over the past week. Valuation Update With 7 Day Price Move • Jul 11
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to €6.79, the stock trades at a forward P/E ratio of 31x. Average forward P/E is 13x in the Chemicals industry in France. Total returns to shareholders of 8.7% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €6.45 per share. Upcoming Dividend • Jun 21
Upcoming dividend of €0.12 per share Eligible shareholders must have bought the stock before 28 June 2024. Payment date: 02 July 2024. Payout ratio is a comfortable 30% and this is well supported by cash flows. Trailing yield: 2.0%. Lower than top quartile of French dividend payers (5.5%). In line with average of industry peers (1.9%). Valuation Update With 7 Day Price Move • May 09
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to €7.42, the stock trades at a forward P/E ratio of 34x. Average forward P/E is 13x in the Chemicals industry in France. Total returns to shareholders of 18% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €6.85 per share. Price Target Changed • Apr 16
Price target decreased by 16% to €6.70 Down from €7.96, the current price target is an average from 4 analysts. New target price is 9.8% above last closing price of €6.10. Stock is down 58% over the past year. The company is forecast to post earnings per share of €0.28 for next year compared to €0.40 last year. Major Estimate Revision • Apr 07
Consensus EPS estimates increase by 53% The consensus outlook for fiscal year 2024 has been updated. 2024 EPS estimate increased from €0.182 to €0.278. Revenue forecast steady at €324.8m. Net income forecast to shrink 19% next year vs 20% growth forecast for Chemicals industry in France . Consensus price target of €7.56 unchanged from last update. Share price rose 6.8% to €6.25 over the past week. New Risk • Apr 01
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 48% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (2.1x net interest cover). Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (1.4% net profit margin). Market cap is less than US$100m (€69.2m market cap, or US$74.6m). Reported Earnings • Mar 29
Full year 2023 earnings: EPS and revenues miss analyst expectations Full year 2023 results: EPS: €0.40 (down from €1.30 in FY 2022). Revenue: €327.6m (down 3.3% from FY 2022). Net income: €4.72m (down 70% from FY 2022). Profit margin: 1.4% (down from 4.6% in FY 2022). Revenue missed analyst estimates by 2.4%. Earnings per share (EPS) also missed analyst estimates by 13%. Revenue is forecast to grow 2.8% p.a. on average during the next 2 years, compared to a 4.8% growth forecast for the Chemicals industry in France. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings. Major Estimate Revision • Mar 28
Consensus EPS estimates increase by 18% The consensus outlook for fiscal year 2024 has been updated. 2024 EPS estimate increased from €0.378 to €0.445. Revenue forecast unchanged at €322.0m. Net income forecast to shrink 59% next year vs 17% growth forecast for Chemicals industry in France . Consensus price target down from €7.96 to €7.76. Share price was steady at €5.76 over the past week. Tillkännagivande • Mar 27
SergeFerrari Group SA Proposes Dividend for Fiscal Year 2023, Payable in July 2024 SergeFerrari Group SA announced that, at the Annual General Meeting of May 16th, 2024, the Group will propose a dividend of €0.12 per share for fiscal year 2023, payable in July 2024. Tillkännagivande • Jan 31
SergeFerrari Group SA to Report Fiscal Year 2023 Results on Mar 26, 2024 SergeFerrari Group SA announced that they will report fiscal year 2023 results After-Market on Mar 26, 2024 Valuation Update With 7 Day Price Move • Jan 25
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to €6.47, the stock trades at a forward P/E ratio of 15x. Average forward P/E is 18x in the Chemicals industry in France. Total returns to shareholders of 6.6% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €12.59 per share. New Risk • Dec 07
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 1.7% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (16% operating cash flow to total debt). Share price has been highly volatile over the past 3 months (10.0% average weekly change). Earnings are forecast to decline by an average of 1.7% per year for the foreseeable future. Minor Risk Dividend is not well covered by cash flows (139% cash payout ratio). Valuation Update With 7 Day Price Move • Nov 21
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to €7.48, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 13x in the Chemicals industry in France. Total returns to shareholders of 31% over the past three years. New Risk • Nov 21
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of French stocks, typically moving 9.8% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (16% operating cash flow to total debt). Share price has been highly volatile over the past 3 months (9.8% average weekly change). Minor Risks Dividend is not well covered by cash flows (139% cash payout ratio). Market cap is less than US$100m (€86.8m market cap, or US$95.0m). Valuation Update With 7 Day Price Move • Nov 03
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to €6.25, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 13x in the Chemicals industry in France. Total returns to shareholders of 15% over the past three years. Major Estimate Revision • Oct 20
Consensus EPS estimates fall by 55% The consensus outlook for earnings per share (EPS) in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from €351.3m to €335.2m. EPS estimate also fell from €0.984 per share to €0.446 per share. Net income forecast to shrink 27% next year vs 2.3% growth forecast for Chemicals industry in France . Consensus price target down from €14.38 to €10.63. Share price fell 24% to €5.79 over the past week. Valuation Update With 7 Day Price Move • Oct 19
Investor sentiment deteriorates as stock falls 20% After last week's 20% share price decline to €6.20, the stock trades at a forward P/E ratio of 9x. Average forward P/E is 15x in the Chemicals industry in Europe. Total returns to shareholders of 2.1% over the past three years. New Risk • Jul 21
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of French stocks, typically moving 6.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (10.0% operating cash flow to total debt). Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (6.1% average weekly change). Price Target Changed • Jul 20
Price target decreased by 11% to €16.33 Down from €18.33, the current price target is an average from 3 analysts. New target price is 37% above last closing price of €11.92. Stock is down 9.3% over the past year. The company is forecast to post earnings per share of €1.18 for next year compared to €1.30 last year. Price Target Changed • May 24
Price target increased by 15% to €18.33 Up from €16.00, the current price target is an average from 3 analysts. New target price is 38% above last closing price of €13.28. Stock is down 14% over the past year. The company is forecast to post earnings per share of €1.36 for next year compared to €1.30 last year. Major Estimate Revision • May 11
Consensus EPS estimates increase by 16% The consensus outlook for fiscal year 2023 has been updated. 2023 EPS estimate increased from €1.17 to €1.36. Revenue forecast steady at €365.6m. Net income forecast to grow 7.6% next year vs 16% growth forecast for Chemicals industry in France. Consensus price target of €17.00 unchanged from last update. Share price rose 3.5% to €13.18 over the past week. Upcoming Dividend • Apr 19
Upcoming dividend of €0.40 per share at 2.8% yield Eligible shareholders must have bought the stock before 26 April 2023. Payment date: 28 April 2023. Payout ratio is a comfortable 31% but the company is not cash flow positive. Trailing yield: 2.8%. Lower than top quartile of French dividend payers (5.4%). Higher than average of industry peers (2.0%). Buying Opportunity • Mar 07
Now 20% undervalued Over the last 90 days, the stock is up 38%. The fair value is estimated to be €19.01, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 25% over the last 3 years. Earnings per share has grown by 58%. For the next 3 years, revenue is forecast to grow by 5.2% per annum. Earnings is also forecast to grow by 14% per annum over the same time period. Price Target Changed • Mar 06
Price target increased by 9.7% to €17.00 Up from €15.50, the current price target is an average from 4 analysts. New target price is 9.7% above last closing price of €15.50. Stock is up 3.9% over the past year. The company is forecast to post earnings per share of €1.27 for next year compared to €0.86 last year. Valuation Update With 7 Day Price Move • Jan 20
Investor sentiment improved over the past week After last week's 15% share price gain to €13.30, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 24x in the Chemicals industry in France. Total returns to shareholders of 119% over the past three years. Price Target Changed • Jan 05
Price target decreased to €15.50 Down from €17.88, the current price target is an average from 4 analysts. New target price is 41% above last closing price of €11.00. Stock is down 16% over the past year. The company is forecast to post earnings per share of €1.24 for next year compared to €0.86 last year. Valuation Update With 7 Day Price Move • Sep 23
Investor sentiment deteriorated over the past week After last week's 16% share price decline to €9.57, the stock trades at a forward P/E ratio of 7x. Average forward P/E is 14x in the Chemicals industry in France. Total returns to shareholders of 55% over the past three years. Valuation Update With 7 Day Price Move • Jun 13
Investor sentiment deteriorated over the past week After last week's 16% share price decline to €13.12, the stock trades at a forward P/E ratio of 10x. Average forward P/E is 14x in the Chemicals industry in France. Total returns to shareholders of 129% over the past three years. Upcoming Dividend • May 12
Upcoming dividend of €0.29 per share Eligible shareholders must have bought the stock before 19 May 2022. Payment date: 23 May 2022. Payout ratio is a comfortable 34% and this is well supported by cash flows. Trailing yield: 1.9%. Lower than top quartile of French dividend payers (5.0%). In line with average of industry peers (1.9%). Price Target Changed • Apr 27
Price target increased to €17.20 Up from €15.88, the current price target is an average from 4 analysts. New target price is approximately in line with last closing price of €17.12. Stock is up 140% over the past year. The company is forecast to post earnings per share of €1.28 for next year compared to €0.86 last year. Price Target Changed • Apr 21
Price target increased to €17.20 Up from €15.25, the current price target is an average from 4 analysts. New target price is approximately in line with last closing price of €17.52. Stock is up 155% over the past year. The company is forecast to post earnings per share of €1.26 for next year compared to €0.86 last year. Valuation Update With 7 Day Price Move • Mar 17
Investor sentiment improved over the past week After last week's 18% share price gain to €18.34, the stock trades at a forward P/E ratio of 15x. Average forward P/E is 19x in the Chemicals industry in France. Total returns to shareholders of 278% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €14.60 per share. Reported Earnings • Mar 09
Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind Full year 2021 results: EPS: €0.86 (up from €0.04 in FY 2020). Revenue: €285.9m (up 46% from FY 2020). Net income: €10.2m (up €9.71m from FY 2020). Profit margin: 3.6% (up from 0.2% in FY 2020). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 1.5%. Earnings per share (EPS) missed analyst estimates by 7.0%. Over the next year, revenue is forecast to grow 8.8%, compared to a 10% growth forecast for the industry in France. Over the last 3 years on average, earnings per share has increased by 41% per year whereas the company’s share price has increased by 43% per year. Valuation Update With 7 Day Price Move • Jan 28
Investor sentiment improved over the past week After last week's 17% share price gain to €14.90, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 20x in the Chemicals industry in France. Total returns to shareholders of 177% over the past three years. Price Target Changed • Jan 26
Price target increased to €15.25 Up from €12.75, the current price target is an average from 4 analysts. New target price is 9.7% above last closing price of €13.90. Stock is up 119% over the past year. The company is forecast to post earnings per share of €0.90 for next year compared to €0.04 last year. Reported Earnings • Sep 10
First half 2021 earnings released: EPS €0.75 (vs €0.21 in 1H 2020) The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: €144.7m (up 82% from 1H 2020). Net income: €8.74m (up 245% from 1H 2020). Profit margin: 6.0% (up from 3.2% in 1H 2020). Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth. Major Estimate Revision • Jul 29
Consensus EPS estimates increase to €0.43 The consensus outlook for earnings per share (EPS) in 2021 has improved. 2021 revenue forecast increased from €260.3m to €273.5m. EPS estimate increased from €0.34 to €0.43 per share. Net income forecast to grow 947% next year vs 12% growth forecast for Chemicals industry in France. Consensus price target up from €9.00 to €10.00. Share price rose 9.3% to €7.49 over the past week. Price Target Changed • Jul 28
Price target increased to €10.00 Up from €8.60, the current price target is an average from 3 analysts. New target price is 32% above last closing price of €7.60. Stock is up 36% over the past year.